These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 36307004)

  • 21. A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density.
    Orwoll E; Teglbjærg CS; Langdahl BL; Chapurlat R; Czerwinski E; Kendler DL; Reginster JY; Kivitz A; Lewiecki EM; Miller PD; Bolognese MA; McClung MR; Bone HG; Ljunggren Ö; Abrahamsen B; Gruntmanis U; Yang YC; Wagman RB; Siddhanti S; Grauer A; Hall JW; Boonen S
    J Clin Endocrinol Metab; 2012 Sep; 97(9):3161-9. PubMed ID: 22723310
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Skeletal responses to romosozumab after 12 months of denosumab.
    McClung MR; Bolognese MA; Brown JP; Reginster JY; Langdahl BL; Shi Y; Timoshanko J; Libanati C; Chines A; Oates MK
    JBMR Plus; 2021 Jul; 5(7):e10512. PubMed ID: 34258507
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab.
    Kendler DL; Bone HG; Massari F; Gielen E; Palacios S; Maddox J; Yan C; Yue S; Dinavahi RV; Libanati C; Grauer A
    Osteoporos Int; 2019 Dec; 30(12):2437-2448. PubMed ID: 31628490
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationship Between Bone Mineral Density and Risk of Vertebral Fractures with Denosumab Treatment in Japanese Postmenopausal Women and Men with Osteoporosis.
    Okubo N; Matsui S; Matsumoto T; Sugimoto T; Hosoi T; Osakabe T; Watanabe K; Takami H; Shiraki M; Nakamura T
    Calcif Tissue Int; 2020 Dec; 107(6):559-566. PubMed ID: 32839843
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Four-Year Teriparatide Followed by Denosumab
    Hirooka Y; Nozaki Y; Okuda S; Sugiyama M; Kinoshita K; Funauchi M; Matsumura I
    Front Endocrinol (Lausanne); 2021; 12():753185. PubMed ID: 34646240
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Updated trabecular bone score accounting for the soft tissue thickness (TBS
    Hans D; Shevroja E; McDermott M; Huang S; Kim M; McClung M
    Osteoporos Int; 2022 Dec; 33(12):2517-2525. PubMed ID: 36115888
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of Teriparatide and Denosumab in Patients Switching From Long-Term Bisphosphonate Use.
    Lyu H; Zhao SS; Yoshida K; Tedeschi SK; Xu C; Nigwekar SU; Leder BZ; Solomon DH
    J Clin Endocrinol Metab; 2019 Nov; 104(11):5611-5620. PubMed ID: 31265071
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis: bone density, mass, and strength of the radius, and wrist fracture.
    Simon JA; Recknor C; Moffett AH; Adachi JD; Franek E; Lewiecki EM; McClung MR; Mautalen CA; Ragi-Eis S; Nicholson GC; Muschitz C; Nuti R; Törring O; Wang A; Libanati C
    Menopause; 2013 Feb; 20(2):130-7. PubMed ID: 23010883
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study.
    McClung MR; Brown JP; Diez-Perez A; Resch H; Caminis J; Meisner P; Bolognese MA; Goemaere S; Bone HG; Zanchetta JR; Maddox J; Bray S; Grauer A
    J Bone Miner Res; 2018 Aug; 33(8):1397-1406. PubMed ID: 29694685
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Denosumab versus alendronate in long-term glucocorticoid users: A 12-month randomized controlled trial.
    Mok CC; Ho LY; Leung SMT; Cheung HN; Chen SPL; Ma KM
    Bone; 2021 May; 146():115902. PubMed ID: 33631355
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial.
    Cheung AM; Tile L; Cardew S; Pruthi S; Robbins J; Tomlinson G; Kapral MK; Khosla S; Majumdar S; Erlandson M; Scher J; Hu H; Demaras A; Lickley L; Bordeleau L; Elser C; Ingle J; Richardson H; Goss PE
    Lancet Oncol; 2012 Mar; 13(3):275-84. PubMed ID: 22318095
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Experience in using Prolia in patients with postmenopausal osteoporosis in clinical practice].
    Skripnikova IA; Kosmatova OV; Abirova ES; Novikov VE; Murashko LM
    Ter Arkh; 2017; 89(12. Vyp. 2):190-196. PubMed ID: 29488480
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.
    Bone HG; Bolognese MA; Yuen CK; Kendler DL; Miller PD; Yang YC; Grazette L; San Martin J; Gallagher JC
    J Clin Endocrinol Metab; 2011 Apr; 96(4):972-80. PubMed ID: 21289258
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Postoperative zoledronic acid for osteoporosis in primary hyperparathyroidism: a randomized placebo-controlled study.
    Ryhänen EM; Koski AM; Löyttyniemi E; Välimäki MJ; Kiviniemi U; Schalin-Jäntti C
    Eur J Endocrinol; 2021 Aug; 185(4):515-524. PubMed ID: 34324430
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Single Infusion of Zoledronate in Postmenopausal Women Following Denosumab Discontinuation Results in Partial Conservation of Bone Mass Gains.
    Everts-Graber J; Reichenbach S; Ziswiler HR; Studer U; Lehmann T
    J Bone Miner Res; 2020 Jul; 35(7):1207-1215. PubMed ID: 31991007
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Skeletal effects of cyclic recombinant human growth hormone and salmon calcitonin in osteopenic postmenopausal women.
    Holloway L; Kohlmeier L; Kent K; Marcus R
    J Clin Endocrinol Metab; 1997 Apr; 82(4):1111-7. PubMed ID: 9100582
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discontinuation of denosumab and associated fracture incidence: analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) trial.
    Brown JP; Roux C; Törring O; Ho PR; Beck Jensen JE; Gilchrist N; Recknor C; Austin M; Wang A; Grauer A; Wagman RB
    J Bone Miner Res; 2013 Apr; 28(4):746-52. PubMed ID: 23109251
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Denosumab Versus Risedronate in Glucocorticoid-Induced Osteoporosis: Final Results of a Twenty-Four-Month Randomized, Double-Blind, Double-Dummy Trial.
    Saag KG; Pannacciulli N; Geusens P; Adachi JD; Messina OD; Morales-Torres J; Emkey R; Butler PW; Yin X; Lems WF
    Arthritis Rheumatol; 2019 Jul; 71(7):1174-1184. PubMed ID: 30816640
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
    Barone A; Giusti A; Pioli G; Girasole G; Razzano M; Pizzonia M; Palummeri E; Bianchi G
    J Am Geriatr Soc; 2007 May; 55(5):752-7. PubMed ID: 17493196
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Denosumab or oral bisphosphonates in primary osteoporosis: a "real-life" study.
    Cairoli E; Palmieri S; Goggi G; Roggero L; Arosio M; Chiodini I; Eller-Vainicher C
    J Endocrinol Invest; 2018 Aug; 41(8):1005-1013. PubMed ID: 29340971
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.